News
Immuneering to evaluate atebimetinib in combination with olomorasib in planned Phase 2 trial in patients with advanced non-small cell lung cancer – CAMBRIDGE, Mass., Aug. 25, 2025 (GLOBE NEWSWIRE) -- ...
© 2001-2025 Plasteurope.com | Imprint | Privacy | Cookie settings ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback